Table 2.

The percentage of clinical isolate of P.aeruginosa growth inhibition in the presence of the tested antibiotics alone and in combination with ZnO NPs at subinhibitory concentrations (1/2 – 1/16 × MIC)

Antibiotic Concentration (μg/ml)	ZnO NPs Concentration (μg/ml)
	0	23.4	46.8	93.7	187.5
Ceftazidime
0	0	32.48 ± 2.08	50.57 ± 3.38	76.78 ± 3.03	93.29 ± 0.82
1	12.29 ± 2.83	46.52 ± 0.47	95.49 ± 1.48	98.32 ± 0.32	99.8 ± 0.75
2	22.96 ± 1.12	93.57 ± 1.60	98.12 ± 0.12	98.88 ± 0.11	100
4	47.52 ± 7.69	99.20 ± 0.46	100	100	100
Tobramycin
0	0	42.44 ± 1.59	57.54 ± 0.67	79.24 ± 1.61	93.15 ± 0.60
0.25	7.68 ± 2.76	81.03 ± 3.07	92.24 ± 1.95	97.12 ± 0.24	97.12 ± 0.24
0.5	25.10 ± 3.24	85.45 ± 1.46	96.51 ± 0.80	100	100
1	62.31 ± 3.03	92.03 ± 0.82	100	100	100
Ciprofloxacin
0	0	45.01 ± 2.64	54.05 ± 1.45	75.87 ± 2.37	94.81 ± 1.65
0.0625	42.51 ± 3.48	74.66 ± 1.16	94.15 ± 0.82	98.59 ± 0.09	98.57 ± 0.25
0.125	78.40 ± 6.10	94.66 ± 0.50	100	100	100
0.25	96.96 ± 0.87	100	100	100	100

ZnO NPs: ZnO nanoparticles